公开(公告)号：US10688105B2

公开(公告)日：2020-06-23

申请号：US15644945

申请日：2017-07-10

Applicant: Macau University of Science and Technology

Inventor： Liang Liu ,  Kam Wai Wong ,  Yuen Kwan Law ,  Cong Ling Qiu

IPC: A61K31/185 ,  A61K31/495 ,  A61K31/56 ,  A61K31/519 ,  A61K31/573 ,  A61K31/165 ,  A61K31/42 ,  A61K45/06 ,  A61K31/635 ,  A61K31/19 ,  A61K39/00 ,  A61K31/365

Abstract: A method for treating a subject suffering from refractory rheumatoid arthritis includes the step of administering an effective amount of a quinonemethide triterpenoid or a pharmaceutically tolerable salt, solvate or anhydrate thereof to the subject. Also is a method for inducing autophagy in a synovial fibroblast, and a method of inducing calcium mobilization in a synovial fibroblast. Further a pharmaceutical composition includes an effective dose of a quinonemethide triterpenoid and an anti-arthritis compound. The quinonemethide triterpenoid is suitable to treat refractory rheumatoid arthritis (RA) in particular ABC-protein-dependent RA and apoptosis-deficient RA. The quinonemethide triterpenoid also possesses significant inhibitory effects on the growth of synovial fibroblasts, in particular modulating the calcium homeostasis in multidrug-resistant rheumatoid arthritis synovial fibroblasts.

公开(公告)号：US20190008872A1

公开(公告)日：2019-01-10

申请号：US15644945

申请日：2017-07-10

Applicant: Macau University of Science and Technology

Inventor： Liang Liu ,  Kam Wai Wong ,  Yuen Kwan Law ,  Cong Ling Qiu

IPC: A61K31/56 ,  A61K31/519 ,  A61K31/573 ,  A61K31/165

Abstract: A method for treating a subject suffering from refractory rheumatoid arthritis includes the step of administering an effective amount of a quinonemethide triterpenoid or a pharmaceutically tolerable salt, solvate or anhydrate thereof to the subject. Also is a method for inducing autophagy in a synovial fibroblast, and a method of inducing calcium mobilization in a synovial fibroblast. Further a pharmaceutical composition includes an effective dose of a quinonemethide triterpenoid and an anti-arthritis compound. The quinonemethide triterpenoid is suitable to treat refractory rheumatoid arthritis (RA) in particular ABC-protein-dependent RA and apoptosis-deficient RA. The quinonemethide triterpenoid also possesses significant inhibitory effects on the growth of synovial fibroblasts, in particular modulating the calcium homeostasis in multidrug-resistant rheumatoid arthritis synovial fibroblasts.